Trajan : Appendix 4D and Half-Year Financial Report - 31 Dec 2021

Trajan Group Holdings Limited 31 December 2021

For personal use only

1. Company details
Name of entity:	Trajan Group Holdings Limited
ABN:	38 152 617 706
Reporting period:	For the half-year ended 31 December 2021
Previous period:	For the half-year ended 31 December 2020
2. Results for announcement to the market
				$'000
Revenues from ordinary activities	Up	17 % to	43,712
Profit from ordinary activities after tax attributable to the owners of Trajan	Down	95 % to	153
Group Holdings Limited
Comprehensive income for the half-year attributable to the owners of	Down	105 % to	(119)
Trajan Group Holdings Limited

Commentary

Trajan Group Holdings Limited listed on 7 June 2021. It should be noted that the results of the previous period for the year ended 31 December 2020 are financial results of the Group prelisting.

The Group reported revenues of $43.7M representing an increase of 16.8% on the previous period. Trajan's two business segments Analytical Products and Life Science Solutions reported improved revenue on the previous period. Analytical Products reported revenue up 12.6% to $28.9M. Life Science Solutions reported segment revenue of $14.8M, up 26.2% on the previous period.

The profit from ordinary activities after tax attributable to the owners of Trajan Group Holdings Limited

amounted to $0.2M (31 December 2021: $3.2M). The movement includes business acquisition expenses of $1.8M, commercialisation costs of $0.7M, restructuring and "Project Neptune", a margin enhancement initiative

related expenses of $0.2M. Adding back these expenses, the profit from ordinary activities after tax is in line with previous period.

3. Dividends

No dividend declared or proposed.

4. Net tangible assets

Reporting Previous

period period

$ $

Net tangible assets per ordinary security

0.19

1,452,500

1 | P a g e

Trajan Group Holdings Limited 31 December 2021

For personal use only

5.	Control gained over entities
Name of entities	Date control gained	Percentage
			holding
Axel Semrau GmBH & Co. KG	18 November 2021	100%
Semrau Immobilien GmbH & Co. KG	18 November 2021	100%
Neoteryx LLC	29 December 2021	100%
Biopsy Solutions Pty Ltd	1 July 2021	100%
6.	Loss of control over entities

During the period, control was not lost over any entity.

7. Details of associates and joint venture entities

There were no associates or joint ventures during the period.

8. Audit review

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

9. Attachments

The Interim Report of Trajan Group Holdings Limited for the half-year ended 31 December 2021 is attached.

Date: 24th February 2022

John Eales AM

Chair

Melbourne

2 | P a g e

Trajan Group Holdings Limited 31 December 2021

For personal use only

Trajan Group Holdings Limited

ABN 38 152 617 706

Interim Financial Report for half-year ended 31 December 2021

3 | P a g e

Trajan Group Holdings Limited 31 December 2021

For personal use only

Dear Shareholders,

At Trajan our success is measured by impact. The impact of our products and services on achieving our goal to enrich well-being through scientific measurement and advance towards personalised, preventative, databased healthcare. Impact is a patient receiving an earlier diagnostic. Impact is data that is more selective, sensitive, and specific. Impact is the confidence of a clinician making decisions based on data that is consistent, reliable, and predictable. Impact is improving the workflow of laboratories. Impact is putting science in the hands of consumers to monitor and prevent illness and support well-being. Impact is measuring the safety of what we consume and where we live. We know if we focus on the impact, commercial success closely aligns.

Our focus on our purpose and our discipline in implementing our strategic direction to deliver meaningful impact has informed our success in the short and longer term. We have delivered ten consecutive years of profitable growth through strong organic growth and by acquiring specialist businesses that either add critical mass to existing products or extend our capabilities through entering new adjacent areas where we see a natural extension to our current products and a strong demand from our customers. With each acquisition we strive for best practice.

Our track record has informed and accelerated our acquisition strategy that was the basis of our successful IPO in June last year, and our transition to a public company is going well. We have successfully executed three new acquisitions and a strategic investment since listing. We added new capability, platforms, and customers to our laboratory automation business with the acquisition of Axel Semrau (November 2021), created a leadership position in blood microsampling with the acquisition of Neoteryx (December 2021), and expanded our laboratory automation consumables capabilities with the acquisition of Leap PAL Parts (December 2021). Added to this we entered consumer portals with a strategic investment into Forth (November 2021) where we have a board position and are exploring partnership opportunities.

These recent acquisitions, and those we continue to target with an active pipeline of complementary companies, aim to utilise and expand the capacity and skillsets of our existing physical global footprint and leadership capability. Acquisition has been, and will continue to be, an important component of our growth. It aims to augment our current business while also adding missing pieces of the puzzle.

Our acquisition program is additive to a strong underlying business, and we continue to see high demand for Trajan's products and services across a diversity of product lines, customers, applications, and geographies.

Trajan remains dynamic as we continue to build global scale, but more importantly we have absolute focus on the future of health and wellness through precise measurement and interpretation of biological, environmental and food samples. We continue to listen carefully to our customer needs and remain deeply embedded in our industry, to both anticipate and predict future trends that present opportunities for Trajan to remain at the fore of enabling best practice. These opportunities will continue to be addressed through our acquisitions and our own technology innovation and development into the future.

Our business is purpose-led through our maxim, 'science that benefits people'. This is an enduring advantage in attracting and retaining talented executives who seek to build a career in a purpose-led,growing, and successful organisation. We thank our teams across the world for the passion and work ethic they bring to their jobs each day, our customers who remain important partners with a shared vision, and our shareholders who continue to support us on our journey.

Yours sincerely

John Eales (Chair)

Stephen Tomisich (Managing Director & CEO)

4 | P a g e

Trajan Group Holdings Limited 31 December 2021

For personal use only

Table of Contents
DIRECTORS' REPORT ………………………………………………………………………………………………..6
AUDITOR'S INDEPENDENCE DECLARATIONS ..........................................................................................	13
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME .........	14
CONSOLIDATED STATEMENT OF FINANCIAL POSITION .........................................................................	15
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY .........................................................................	16
CONSOLIDATED STATEMENT OF CASH FLOWS ......................................................................................	17
NOTES TO FINANCIAL STATEMENTS .........................................................................................................	18
DIRECTORS' DECLARATION ........................................................................................................................	37
INDEPENDENT AUDITOR'S REVIEW REPORT ...........................................................................................	38

5 | P a g e